Logo

Sanofi and Regeneron Report the US FDA’s Acceptance of sBLA for Dupixent with Priority Review to Treat COPD with Type 2 Inflammation

Share this
Sanofi

Sanofi and Regeneron Report the US FDA’s Acceptance of sBLA for Dupixent with Priority Review to Treat COPD with Type 2 Inflammation

Shots:

  • The US FDA has accepted & granted priority review to the sBLA of Dupixent as an add-on maintenance therapy for uncontrolled COPD adults having type 2 inflammation with the decision expected on Jun 27, 2024. The regulatory submissions in China & the EU are under review
  • The sBLA plus the worldwide submissions are based on P-III studies determining Dupixent's safety & efficacy in uncontrolled COPD with type 2 inflammation adult smokers (current/former) already on background maximal SoC inhaled therapy
  • The studies (BOREAS, NOTUS) depicted moderate/severe acute COPD exacerbation reduction by 30% & 34% with Dupixent respectively vs PBO, and a sustained improvement in lung function at 52wks.

Ref: Globe Newswire | Image: Sanofi

Related News:- Sanofi Reports Dupixent’s (dupilumab) US Label Update for its Use in Atopic Dermatitis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions